Published date: 13 July 2022

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 25 July 2022, 5pm

Contract summary

Industry

  • Medical equipments, pharmaceuticals and personal care products - 33000000

Location of contract

HD8 0LE

Value of contract

£87,500 to £100,000

Procurement reference

Paxman 1119795

Published date

13 July 2022

Closing date

25 July 2022

Closing time

5pm

Contract start date

8 August 2022

Contract end date

28 February 2023

Contract type

Service contract

Procedure type

Open procedure (below threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements below the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

Description

Paxman is a medical technology company with an established leadership position in the Scalp
Cooling sector. The Paxman Scalp Cooling System (PSCS) minimizes hair loss in connection with chemotherapy treatment. The product is distributed to over 60 markets internationally, including: France, Germany, The Netherlands, Switzerland, Sweden, Russia, Brazil, Mexico, Australia, and the U.S. Scalp cooling is an important treatment, which has a strong clinical support and is a fully established therapy in many countries throughout the world.

Chemotherapy-induced alopecia is the most feared side effect of treatment in >75% of patients. Often patients feel this is the most traumatic side effect of their cancer treatment and not only can it lead to social isolation, but hair loss can affect self-image more than breast surgery. Eight percent of patients refuse chemotherapy or request a less efficacious treatment due to the prospect of hair loss.

The company has extensive global experience - since 2003, more than 65 clinical studies have been conducted in more than 17 countries and includes the first-ever randomized clinical trial to evaluate modern scalp cooling, which took place at several Cancer Centers in the United States as part of the FDA (Food and Drug Administration) clearance process.

As part of Paxman's investment in biological research, it has been discovered that chemotherapy drugs induce oxidative stress inside cells of the hair follicles which causes cell toxicity (and ultimately hair loss).

Therefore, a novel patented combinatorial approach was designed to reduce cell toxicity at "sub-optimal" cooling temperatures and has the potential to dramatically enhance the efficacy of the Paxman scalp cooling device.

This intervention combines cooling with treatment with a reactive oxygen species (ROS) inhibitor (antioxidant compound) delivered into cells to reduce oxidative stress (and these findings have been confirmed using whole follicles mini-organ cultures).

Using in vitro models, the company have now established a panel of antioxidant compounds which has shown extremely good efficacy in minimising or preventing cytotoxicity in combination with cooling.

Paxman now need the expertise to be able to target these antioxidant compounds to human hair follicles of the scalp. This will require expertise in pharmaceutics in order to prepare topical agents with appropriate formulations for delivery of these antioxidants to the hair follicles.

The identified third-party organisation must have both the cell biology/skin research as well as pharmaceutics expertise and research capabilities in order to be in position to deliver the proposed project.

More information

Attachments

About the buyer

Contact name

Liza Hirst

Address

International House,Penistone Road, Fenay Bridge
HUDDERSFIELD
HD80LE
England

Telephone

01484349444

Email

liza@paxmanscalpcooling.com

Website

www.paxmanscalpcooling.com